Confirmed risk of heart inflammation in children

“Including children and adolescents in vaccination strategies against SARS-CoV-2 and its subspecies is not unreasonable, but it seems unwise,” said Jean-Marc Sabatier*. I’m here. interview.

The European Medicines Agency (EMA) recently approved mRNA vaccines from Moderna (Spikevax) and Pfizer-Biontech (Cormirnaty) for use in children/adolescents aged 12 to 17 in 27 countries of the European Union. This decision contrasts with the WHO opinion of 21 July 2021 not to recommend her Covid-19 vaccine for this age group. Why such conflicting opinions from the most important health authorities in this field?

WHO, contrary to the European Medicines Agency, must consider the unfavorable benefit/risk ratio of vaccination for the youngest. This is also my opinion given the current data on SARS-CoV-2 and Covid-19.

Children/adolescents, unlike adults, are less susceptible to severe infection with SARS-CoV-2 and its variants (except for special cases of comorbidities).
As of July 22, 2021, Approximately 4.13 million children worldwide are infected with SARS-CoV-2 Since the beginning of the pandemic. Currently, about 20% of those infected are children or adolescents (under the age of 18). According to the CDC (Centers for Disease Control and Prevention), the total number of children/adolescents (up to age 18) is 335 people have died from Covid-19 as of 20 July 2021.

Independent of the degree of protection conferred by the presence of cross-immunity with other benign seasonal coronaviruses, this low susceptibility of children/adolescents (especially young children) to SARS-CoV-2 infection is primarily due to renin. -Angiotensin system (RAS) is different from adults. It is a complex and ubiquitous hormonal/physiological system involving the renal, pulmonary and cardiovascular autonomic nervous system (heart, lung, kidney, liver, gut, brain, vasculature, testicles, skin and many others). found in tissues and organs). function. This system, which plays a central role in the functioning of the human (and mammalian) body, is specifically targeted by the SARS-CoV-2 virus.
Dysfunctional RAS is the cause of Covid-19 disease. Such RAS dysfunction is induced by binding of SARS-CoV-2 (or vaccine Spike protein) to the ACE2 (angiotensin-converting enzyme 2) receptor on human target cells.

Are there any differences between children and adults?

Indeed, several scientific studies have highlighted important differences between RAS in children and adults. Therefore, even in the same person, RAS varies from birth to death.
According to recent research Differences in the distribution/density of the RAS receptor ACE2 (target of the virus) in nasal and pulmonary alveolar epithelial cells.
In addition, RAS ‘drives’ the release of cytokines associated with inflammatory processes and innate immunity that differs between children and adults. For example, young children have potent anti-SARS-CoV-2 protection via recruitment of eosinophilic granulocytes (recruitment is not observed in adults). There is also a protective lymphoid tissue associated with the bronchi called ‘BALT’ (which is a functional unit that promotes antimicrobial immunity by eliminating or ‘clearing’ pathogens). This is accompanied by a reduction in the production of highly damaging pro-inflammatory cytokines (cytokine storm) that are responsible for the evolution of Covid-19 to severe forms.
Therefore, infection of children or adolescents with SARS-CoV-2 leads to a very, very rare, very severe or fatal form of the disease. The fatality rate for people in this age group infected with the virus is almost non-existent to this day.

Should young people be vaccinated to prevent infection with the virus?

This point is very important. In my opinion, it does not justify immediate vaccination of young people. In fact, as recent research has shown, vaccinating an individual does not block the virus from infecting other individuals. In other words, vaccination does not prevent viral infection.
Finally, are there any risks of vaccinating young people?

There are potential risks associated with vaccinating children (and adults), even if they are small. These dangers are based on:

1. Ignoring “harmful” side effects that may be associated with vaccination against SARS-CoV-2 in the long or short term.
2. So far, the only mRNA vaccine use approved by the Health Authority (AEM) for children/adolescents aged 12-17 years. In fact, they are the first vaccines based on messenger RNA technology to be used in humans, meaning that potential long-term adverse effects have been discovered. , including children and adolescents in vaccination strategies against SARS-CoV-2 and its variants. But let’s not forget that the “classic” vaccines in use today in children and adolescents have saved millions of lives over the last few decades. While this does not negate the usefulness of vaccines whose value has already been proven, it does caution against the unfavorable benefit/risk ratio of vaccination against SARS-CoV-2 for young people aged 12 years and older. is what you do. In conclusion, remember that statistics show that the younger you are, the less likely you are to develop a severe form of COVID-19.*Jean-Marc Sabatier, PhD in Cell Biology and Microbiology, Research Director, CNRS, Institute of Neurophysiology and Pathology (INP), University of Aix-Marseille
   

   Advocating for Youth Immunization

   In June 2021, two doctors, Dr. Stanley A. Plotkin and Dr. Ofer Levy, two of the leading authorities on vaccination, published in Pediatrics, a journal of the American Academy of Pediatrics, “Mandatory vaccines for children against COVID-19.” We published an article titled “Considering. In it, two vaccine experts explain that vaccination from age 12 to her 17 protects adults. We now know this is not true. But it is probably thanks to this publication that authorities in several countries, including France, have decided to vaccinate young people from her 12 to her 17 years.
   However, it should be noted that both doctors have links of interest to big pharmaceutical companies, as stated in the journal: Dr. Levy is the inventor of his adjuvant patent application for a pending vaccine, and in 2019 he served as a consultant to GSK. ”
   Get photo.